Stablepharma announces addition to advisory board

The company’s patented StablevaX technology is designed to thermally stabilise and deliver vaccines without the requirement for refrigeration

Professor Saul Faust has accepted a position on Stablepharma’s advisory board. Faust is currently leading the UK national 3rd dose COVID-19 vaccine booster trial.

“Professor Faust is a fantastic addition to the Stablepharma’s Advisory Board, especially at a time when vaccine solutions are at the forefront of everyone’s mind,” says Özgür Tuncer, CEO & Executive Director, Stablepharma.

The company’s patented StablevaX technology is designed to thermally stabilise and deliver vaccines without the requirement for refrigeration. A stabilised vaccine solution could eliminate the need for the cold chain and enable stockpiling anywhere in the world, the company claims.

“We are making significant progress with our Tetadif-Td programme in partnership with the European vaccine manufacturer BulBio, and we are now receiving very encouraging potency data from our animal challenge trials. This positive data has accelerated our plans to get Tetadif - StablevaX into first-in-human clinical trials. As a result, we are embarking on a Series A funding round in order to fund our upcoming clinical trials and scale up our GMP manufacturing”, added Tuncer.

“Our aim with the StablevaX invention is to ensure that most vaccines can be removed from the refrigerated cold chain and stored for months or even years at room temperature’ says Dr Bruce Roser, Chairman & Founder. ‘Having Professor Faust on our team will be a significant boost to our abilities”.

Nick Child, VP & Co Founder, Stablepharma added: “We are flattered that Professor Faust has agreed to join our advisory board as he brings with him significant expertise in designing and conducting first in human clinical trials, achievement of which is of course our end game for the StablevaX Td vaccine, hopefully the world’s first fridge free vaccine”.

Professor Saul Faust commented: “I am delighted to be able to work with Stablepharma, especially to support clinical trials to demonstrate the safety and efficacy of the StablevaX approach for vaccines to be transported globally without the need for complex and expensive cold chain management”.

Companies